Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2020

Autores

Fernandes, E (Autor) Outra; Sores, J (Autor) Outra; Cotton, S (Autor) Outra; Peixoto, A (Autor) Outra; Ferreira, D (Autor) Outra; Freitas, R (Autor) Outra; Celso Reis (Autor) ICBAS; Santos, LL (Autor) Outra; Ferreira, JA (Autor) Outra

Revista

A Revista está pendente de validação pelos Serviços Administrativos.

Título: THERANOSTICS

Vol. 10

Páginas: 4903-4928

ISSN: 1838-7640

Editora: IVYSPRING INT PUBL

Indexação

ISI Web of Knowledge - 23 Citações

Scopus - 22 Citações

Outras Informações

ID Authenticus: P-00S-1WD

DOI: 10.7150/thno.42480

Abstract (EN): Esophageal (OC), gastric (GC) and colorectal (CRC) cancers are amongst the digestive track tumors with higher incidence and mortality due to significant molecular heterogeneity. This constitutes a major challenge for patients' management at different levels, including non-invasive detection of the disease, prognostication, therapy selection, patient's follow-up and the introduction of improved and safer therapeutics. Nevertheless, important milestones have been accomplished pursuing the goal of molecular-based precision oncology. Over the past five years, high-throughput technologies have been used to interrogate tumors of distinct clinicopathological natures, generating large-scale biological datasets (e.g. genomics, transcriptomics, and proteomics). As a result, GC and CRC molecular subtypes have been established to assist patient stratification in the clinical settings. However, such molecular panels still require refinement and are yet to provide targetable biomarkers. In parallel, outstanding advances have been made regarding targeted therapeutics and immunotherapy, paving the way for improved patient care; nevertheless, important milestones towards treatment personalization and reduced off-target effects are also to be accomplished. Exploiting the cancer glycoproteome for unique molecular fingerprints generated by dramatic alterations in protein glycosylation may provide the necessary molecular rationale towards this end. Therefore, this review presents functional and clinical evidences supporting a reinvestigation of classical serological glycan biomarkers such as sialyl-Tn (STn) and sialyl-Lewis A (SLe(A)) antigens from a tumor glycoproteomics perspective. We anticipate that these glycobiomarkers that have so far been employed in non-invasive cancer prognostication may hold unexplored value for patients' management in precision oncology settings.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 26